Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Operating Income Loss of -$403.36 million for the year ending 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -2.0% in Operating Income Loss from 2024 to 2025.
- This data is from IOVANCE BIOTHERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), IOVANCE BIOTHERAPEUTICS, INC.'s Operating Income Loss has declined by 2,557,318.2%.
- Historical annual values: Fiscal year 2025: -$403.36 million | Fiscal year 2024: -$395.28 million | Fiscal year 2023: -$460.56 million | Fiscal year 2022: -$398.88 million | Fiscal year 2021: -$342.70 million | Fiscal year 2020: -$261.94 million | Fiscal year 2019: -$206.87 million | Fiscal year 2018: -$128.26 million | Fiscal year 2017: -$92.88 million | Fiscal year 2016: -$53.64 million | Fiscal year 2015: -$27.86 million | Fiscal year 2014: -$12.04 million | Fiscal year 2013: -$22.64 million | Fiscal year 2012: -$8.13 million | Fiscal year 2011: -$21.22 million | Fiscal year 2010: -$815.4 thousand | Fiscal year 2009: -$15.8 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: